CTA056 is a potent and selective ITK inhibitor (interleukin-2-inducible T-cell kinase inhibitor). ITK is a member of the Btk (Brutons tyrosine kinase) family of tyrosine kinases, plays an important role in normal T-cell functions and in the pathophysiology of both autoimmune diseases and T-cell malignancies. CTA056 exhibits the highest inhibitory effects toward Itk, followed by Btk and endothelial and epithelial tyrosine kinase. Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. CTA056 may be potential therapeutic agent for the treatment of T-cell leukemia and lymphoma.

MedKoo Cat#: 406282 Name: CTA056 CAS#: 1265822-30-7 Chemical Formula: C35H34N6O Exact Mass: 554.27941 Molecular Weight: 554.68 Elemental Analysis: C, 75.79; H, 6.18; N, 15.15; O, 2.88

Synonym: CTA056; CTA-056; CTA 056

IUPAC/Chemical Name: 7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin-4-yl)phenyl)-1H-imidazo[4,5-g]quinoxalin-6(5H)-one

InChi Key: BSSBAJKNZOHHCA-UHFFFAOYSA-N

InChi Code: InChI=1S/C35H34N6O/c42-35-32(22-25-8-3-1-4-9-25)37-30-24-33-31(23-29(30)39-35)38-34(41(33)21-7-20-40-18-5-2-6-19-40)28-12-10-26(11-13-28)27-14-16-36-17-15-27/h1,3-4,8-17,23-24H,2,5-7,18-22H2,(H,39,42)

SMILES Code: O=C1NC2=CC3=C(N(CCCN4CCCCC4)C(C5=CC=C(C6=CC=NC=C6)C=C5)=N3)C=C2N=C1CC7=CC=CC=C7

Technical Data

Appearance: Yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code: 293490

Additional Information

        

References

1: Guo W, Liu R, Ono Y, Ma AH, Martinez A, Sanchez E, Wang Y, Huang W, Mazloom A, Li J, Ning J, Maverakis E, Lam KS, Kung HJ. Molecular characteristics of CTA056,  novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets   malignant T cells and modulates oncomirs. Mol Pharmacol. 2012 Nov;82(5):938-47. doi: 10.1124/mol.112.079889. Epub 2012 Aug 16. PubMed PMID: 22899868; PubMed Central PMCID: PMC3477223.